David Healy papers (Collection Biomed 433)
Finding aid prepared by Kathryn Hale; machine-readable finding aid created by Caroline Cubé.
The processing of this collection was generously supported by Arcadia.
Louise M. Darling Biomedical Library History and Special Collections for the Sciences
History and Special Collections Division for the Sciences
URL: http://www.library.ucla.edu/specialcollections/biomedicallibrary/history-special-collections-sciences
2013 The Regents of the University of California. All rights reserved. David Healy papers (Collection Biomed 433) Title: David Healy papers Collection number: Biomed 433 Contributing Institution: Louise M. Darling Biomedical Library History and Special Collections for the Sciences
History and Special Collections Division for the Sciences
Language of Material: English Physical Description: 13.2 linear ft.(35 document boxes and 1 record carton box) Date (bulk): Bulk, 1978-2000 Date (inclusive): 1950-2001 Abstract: The David Healy Papers collection consists of a draft of David Healy’s monograph and all associated interview
transcripts/supplementary materials from his published oral history of psychopharmacology ( The Psychopharmacologists,
Vols. I-III). It also contains research and testimony from multiple legal cases on pharmaceutical product liability concerning
the treatment of depression, including specific arguments about the pharmaceutical industry’s knowledge of the
relationships between Selective Serotonin Reuptake Inhibitors (SSRIs) and suicide. The collection’s legal materials include
raw data from fluoxetine’s clinical trials, which occurred while the product was seeking FDA approval, before it was
launched in the U.S. in 1988. These data show the co-prescription of benzodiazepines during Randomized Control Trials to
counteract the activating properties of fluoxetine. Pertinent legal cases include the Jefferson Circuit court case, Fentress v.
Shea Communications and Eli Lilly (the first SSRI case to go to trial rather than be settled outside of court), as well as the
following U.S. District Court cases: Susan Forsyth et al. v. Eli Lilly, Miller et al. v. Pfizer Incorporated, Motus v. Pfizer
Incorporated, and Tobin v. SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline). All of these legal cases were
synthesized and published in David Healy’s 2004 book entitled Let Them Eat Prozac: The Unhealthy Relationship betweenthe Pharmaceutical Industry and Depression. Language of Materials: Materials are primarily in English, with one set of interviews from The Psychopharmacologists
conducted in French and one other interview conducted with the aid of a German translator. Some additional materials are
Physical Location: Stored off-site at SRLF. Advance notice is required for access to the collection. Please contact the UCLA
Library Special Collections Reference Desk for paging information. Restrictions on Access
COLLECTION STORED OFF-SITE AT SRLF: Open for research. All materials are stored off site and require advance notice for
use. Please contact History and Special Collections for the Sciences, UCLA Louise M. Darling Biomedical Library,
Restrictions on Use and Reproduction
Property rights in the physical objects belong to the UCLA Biomedical Library. Literary rights, including copyright, are
retained by the creators and their heirs. It is the responsibility of the researcher to determine who holds the copyright and
pursue the copyright owner or his or her heir for permission to publish if the Biomedical Library does not hold the copyright. Preferred Citation
[Identification of item], David Healy papers (Biomed Collection 433). Louise M. Darling Biomedical Library History and
Special Collections for the Sciences, University of California, Los Angeles. Provenance/Source of Acquisition
Collection was donated by Dr. David Healy, July 2011. Processing Information
Processed by Kathryn Hale, M.A., in 2013 in the Center for Primary Research and Training (CFPRT), with assistance from
General note
This collection forms part of the UCLA/ACNP History of Neuropsychopharmacology Archives. Biography/History
David Healy is an internationally recognized psychiatrist, researcher, and author from Ireland. He has served as a former
Secretary of the British Association for Psychopharmacology, and he is a founder and Chief Executive Officer of Data Based
Medicine Americas Limited, which aims to collect direct patient reports of drug effects through their website (RxISK.org)
and use them to affect regulatory policy. He has published extensively on the history of psychopharmacology and
psychiatry, issues with medical ghost writing, SSRI use and suicide risk, Explanatory Models of mental illness and the
historical shaping of categories for mental illness. David Healy papers (Collection Biomed 433)
David Healy was born in Raheny, Dublin on April 27, 1954. He completed his medical degree in neuroscience and studied
psychiatry during a clinical research fellowship at Cambridge University. He is currently a professor of Psychiatry at CardiffUniversity School of Medicine, Wales, and the head of the psychiatric inpatient unit at Bangor University, North Wales. To
date, Healy has published 20 books and over 150 peer-reviewed articles, as well as over 200 other pieces. Well-known
works include The Psychopharmacologists (Vols. I-III, 1996-2000), The Antidepressant Era (1999), and Let Them Eat Prozac
(2004). He has also generated independent data (see Healy 2000) that speaks directly to the Fentress trial and raises the
need for transparency in psychopharmaceutical clinical trials. His data suggests a causal link between patients’ ingestion of
sertraline (Zoloft) and increased suicidality in two of twenty healthy volunteers when compared to reboxetine (a non-SSRI
antidepressant), which he attributed to emotional disinhibition and feelings of inner restlessness.
In 1994, before David Healy was aware of the Fentress case and legal developments regarding SSRIs, he was approached
by CNS Drugs to write a review article about fluoxetine and the suicide controversy. This publication led to Healy’s
subsequent involvement in the Forsyth, Miller, Motus, and Tobin cases, including serving as an expert witness in the
Forsyth v. Eli Lilly and Company case in 1999 and the Tobin v. SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline)
case in 2001. Healy was deposed in the Miller v. Pfizer Inc. case in 2004, but his testimony on general and specific
causation (about whether Zoloft can cause suicide and it if caused Matthew Miller to commit suicide) was later excluded as
a result of the Daubert Supreme Court hearing, which generated principles for when expert testimony reflects scientific
knowledge. (The Motus case was eventually thrown out due to Zoloft’s prescription-only status.) The Tobin case returned
the first verdict against a pharmaceutical company for adverse behavioral effects of a psychotropic drug (Paxil). This
verdict contributed to the 2003 UK Medicines and Healthcare Products Regulatory Agency’s decision to caution physicians
that Seroxat (Paxil) was “contra-indicated” in children under 18 for the treatment of depression. It also influenced the 2004
FDA hearing on the use of SSRIs in children and the subsequent FDA requirement that a “black box” warning label be
An important historical event to consider alongside the records in this collection is The Toronto Affair. In early 2000, Healy
had been hired as a professor of Psychiatry at the University of Toronto and the Head of the Mood and Anxiety Disorders
Program within the Center for Addiction and Mental Health, although he was waiting on his visa and had not yet made the
move from Britain to Canada. In November of 2000, he was invited to the University of Toronto’s Department of Psychiatry
to speak at its seventy-fifth anniversary meeting, which was entitled “Looking Back: Looking Ahead.” The chief physician at
the Center for Addiction and Mental Health, David Goldbloom, reacted strongly to his talk, and soon after, the Center
withdrew their offer of a position. Healy later became aware that Eli Lilly had, some time prior, donated $1.5 million dollars
to the Centre for Addiction and Mental Health, which had hired Healy, and although there was no direct evidence that Eli
Lilly attempted to terminate this appointment, broader questions were raised about possible conflicts of interest between
the pharmaceutical industry and academia. Healy published two articles (Healy 2002, 2003) recounting this event and the
possible conflicts of interest it raises between the pharmaceutical industry and academia. Later, he filed a legal action
against the University of Toronto seeking redress for breach of contract and violation of academic freedom. This legal
action was settled in April 2002. However, this experience overlapped with his involvement in the Tobin case and likely
affected his writing of Let Them Eat Prozac and The Creation of Psychopharmacology. Both of these works were being
written during that time period and address issues that arise when pharmaceutical companies’ funding of research
programs conflicts with academic freedom.
Resources used while creating this finding aid:
Healy, David. Let them eat Prozac: The unhealthy relationship between the pharmaceutical industry anddepression. New York University Press, 2004.
Healy, David. "Conflicting interests in Toronto: Anatomy of a controversy at the interface of academia and
industry." Perspectives in biology and medicine 45.2 (2002): 250-263.
Healy, David. "In the grip of the python: conflicts at the university-industry interface." Science and engineeringScope and Content
Materials are largely textual, comprising personal and professional correspondence; publications; patient charts from Eli
Lilly; official court records, including deposition transcripts, transcripts of trial testimony, and court exhibit files from
multiple cases; and internal documents from Eli Lilly and Company. Other formats found in the collection include photographs of interviewees from The Psychopharmacologists, ephemera such as one or two pharmaceutical
David Healy papers (Collection Biomed 433)
advertisements, films associated with the work of two prominent psychopharmacologists (namely, Mogens Schou and Jean
Thuillier), and video recordings of case proceedings and depositions from three cases (Fentress et al. v. SheaCommunications and Eli Lilly and Co., Motus v. Pfizer Inc., and Miller et al. v. Pfizer Inc.) Strengths of this collection include
the corpus of patient charts (along with notes from treating staff and Eli Lilly), correspondence and draft revisions regardingThe Psychopharmacologists, and unique access to personal correspondence with well-known researchers in the area, such
as Frank Ayd, Thomas Ban, Arvid Carlsson, Louis Lasagna, Judith Rapoport, and Myrna Weissman. Organization and Arrangement
The collection was received in good condition and an arrangement scheme based on topical organization had already been
imposed. Overall, these 3 series were arranged chronologically based on the bulk dates with some exceptions explained in
the series and subseries descriptions below.
1. Fentress et al. v. Shea Communications and Eli Lilly and Company, 1970-2001
1.1. Data from Prozac registration files, 1978-2000
3. The Psychopharmacologists, 1950-2001
Physical Characteristics and Technical Requirements
This collection includes three Betacam digital tapes, forty-one VHS tapes, and seven PAL/UK format VHS tapes. Related Material
The following sources provide additional information on Eli Lilly:
UCLA Library Special Collections, History and Special Collections for the Sciences
Stanford University – Medical History Center
Indiana State Library – Manuscripts and Rare Books
The following sources provide additional information on interviewees included in David Healy’s multivolume set, The
UCLA Center for the Study of the History of Neuropsychopharmacology
National Library of Medicine – Archives and Manuscripts
David Healy papers (Collection Biomed 433)
Series 1: Fentress et al. v Shea Communications and Eli Lilly and Company. 1970-2001.
Subseries 1.1: Data from Prozac registration files. Bulk, 1978-1985. 1978-2000. Series 1: Fentress et al. v Shea Communications and Eli Lilly and Company.1970-2001. Processing/Project Information
Videos included in Series 1 were minimally processed at the box level. Scope and Content
Series 1 contains court proceedings, case evidence, and correspondence connected to the
consolidated multidistrict legislation for Fentress et al. v. Shea Communications and Eli Lilly
and Company (“Fentress”) court case that played an substantial role in David Healy’s book,
Let Them Eat Prozac. This was the first of 160 pending cases against Prozac to go to trial. A
verdict was rendered in Kentucky in the autumn of 1994. The case was originally decided in
favor of Eli Lilly (with a vote of 9:3), but unclear wording during the case, compounded by
questions of whether this case had been quietly settled outside of court, led Judge John
Potter to offer the plaintiffs’ attorneys the possibility of a retrial. Judge Potter entered a
judgment on January 25, 1995, in which he adjudicated that the claims against the
defendant be dismissed with prejudice. The case subsequently went to Kentucky Supreme
This product liability case stemmed from Joseph Wesbecker taking Prozac for approximately
one month in 1989. As reported by family members, he became visibly agitated and
unkempt during that period. Then, on September 14, 1989, he returned to his place of
employment, Standard Gravure [owned by Shea Communications] in Indianapolis with
several guns, killed eight of his former colleagues, wounded twelve others, and finally killed
himself. The Fentress case was named for one of Wesbecker’s victims. Subseries 1.1: Data from Prozac registration files.Bulk, 1978-1985.1978-2000. Scope and Content
Subseries 1.1 contains patient chart data [with identifying information redacted] from the
early phase II and phase III Prozac registration files (1978-1988), which were originally
acquisitioned for evidentiary use in the Fentress case. This subseries also contains
handwritten notes that David Healy made on the charts while assessing their contents for
research purposes. Patient charts come from the following study trials: HCAA, HCAB,
HCAC, HCAD, HCAF, and HCCG. Access to these charts (which compose much of the
product’s registration file) is highly valuable given that Prozac began active marketing of
the medication after obtaining final U.S. Food and Drug Administration approval in 1987.
As the largest subseries of this collection, it provides a detailed glimpse into clinical trial
data and even includes a partial treatment randomization key that Healy obtained from
legal counsel. Charts show inpatient/outpatient status, alterations to diagnosis, dosage
accounting, symptom rating scales, discharge summaries, requests for “compassionate
use” extensions, and reported reasons for early termination. Researchers should take
note that, according to the Zapapas deposition, the two-letter code assigned to fluoxetine
was HC, and study trials follow the alphabet starting with AA. Organization and Arrangement
There are a couple important arrangement notes to take into account for subseries 1.1.
First, all patient charts were arranged by study number (including HCAA, HCAB, HCAC,
HCAD, HCAF, and HCCG), protocol number or investigator number, and patient
identification number. Duplicates of some HCAA, HCAB, and HCAC charts exist in the
collection and were retained because the copies had missing pages, revealed
alterations/corrections to patient charts, or included handwritten notes/post-it-note tags
that were deemed to have significant research value. Additionally, and more specifically,
HCAF investigators #1 and #6 were intermittently renamed as investigator #999 on
some patient charts, but the original numbers were kept on folder labels for consistency
Legal correspondence with Healy: Treatment randomization key.2000 September HCAA investigator 1, patient 0001.1978 February-1978 April. HCAA investigator 1, patient 0002.1978 March-1978 April, 1978 June. David Healy papers (Collection Biomed 433)
Series 1: Fentress et al. v Shea Communications and Eli Lilly and Company. 1970-2001.
Subseries 1.1: Data from Prozac registration files. Bulk, 1978-1985. 1978-2000. HCAA investigator 1, patient 0003.1978 May-1978 June. HCAA investigator 1, patient 0004.1978 September - 1978 October, 1978 November. HCAA investigator 1, patient 0008.1978 December - 1979 January. HCAA investigator 1, patient 0009.1978 December - 1979 February. HCAA investigator 1, patient 0011.1979 November, 1980 February. HCAA protocol 7, patient 0001.1978 February - 1978 April. HCAA protocol 7, patient 0002.1978 March - 1978 April. HCAA protocol 7, patient 0005.1978 October - 1978 November. HCAA protocol 7, patient 0006.1978 October - 1978 November. HCAA protocol 7, patient 0007.1978 October - 1978 November. HCAA protocol 7, patient 0008.1978 December - 1979 January. HCAA protocol 7, patient 0009.1978 December - 1979 February. HCAA protocol 7, patient 0011.1979 November. HCAA protocol 9, patient 0012.1978 March - 1978 July. HCAA protocol 9, patient 0013.1978 March - 1978 May. HCAA investigator 2, patient 0014.1978 April - 1978 August. HCAA protocol 9, patient 0015.1978 May - 1978 June. HCAA protocol 9, patient 0017.1978 July - 1978 September. HCAA investigator 2, patient 0019.1978 August - 1978 September. HCAA investigator 2, patient 0020.1978 September - 1978 November. HCAA investigator 2, patient 0022.1978 October - 1979 January. HCAA investigator 2, patient 0026.1979 August - 1979 September, 1979 October - 1980 February. HCAA protocol 9, patient 0027.1979 September - 1980 January. HCAA protocol 13, patient 0036.1978 September - 1978 October. HCAA investigator 3, patient 0040.1978 November - 1978 December. HCAA investigator 3, patient 0042.1979 March - 1979 April. HCAA protocol 13, patient 0044.1979 November - 1979 December. HCAA protocol 10, patient 0021.1978 November - 1978 December. HCAA investigator 4, patient 0025.1979 April - 1979 May, 1978 December - 1982 December. HCAA investigator 4, patient 0026.1979 August- 1979 September. HCAB protocol 14, patient 0001.1979 April. HCAB protocol 14, patient 0002.1979 April - 1979 May. HCAB protocol 14, patient 0003.1979 April - 1979 December. HCAB protocol 14, patient 0004.1979 April - 1979 June. HCAB protocol 14, patient 0005.1979 May - 1979 June. HCAB protocol 14, patient 0006.1979 May - 1979 June. HCAB protocol 14, patient 0007.1979 June - 1979 August. HCAB protocol 14, patient 0010.1979 July - 1979 August. HCAB protocol 14, patient 0011.1979 August-1979 September, 1982 February. HCAB protocol 14, patient 0012.1979 September. HCAB protocol 14, patient 0013.1979 September - 1979 November. HCAB protocol 14, patient 0014.1979 September - 1979 October. HCAB protocol 14, patient 0015.1979 September - 1979 October. HCAB investigator 3, patient 0011.1980 September - 1980 November. HCAB protocol 16, patient 0101.1979 April - 1979 May. HCAB protocol 16, patient 0102.1979 June - 1979 July. HCAB protocol 16, patient 0103.1979 June - 1979 August. HCAB protocol 16, patient 0104.1979 July. HCAB protocol 16, patient 0105.1979 June - 1979 August. HCAB protocol 16, patient 0106.1979 August - 1979 September. HCAB protocol 17, patient 0001.1979 July - 1979 August. HCAB protocol 17, patient 0002.1979 July - 1979 August. HCAB protocol 17, patient 0005.1979 December - 1980 January. HCAB protocol 17, patient 0008.1980 February - 1980 March. HCAB protocol 17, patient 0009.1980 August - 1980 October. David Healy papers (Collection Biomed 433)
Series 1: Fentress et al. v Shea Communications and Eli Lilly and Company. 1970-2001.
Subseries 1.1: Data from Prozac registration files. Bulk, 1978-1985. 1978-2000. HCAB protocol 17, patient 0010.1980 August - 1980 September. HCAB protocol 17, patient 0011.1980 September - 1980 November. HCAC investigator 1, patient 0001.1979 November - 1980 January. HCAC investigator 1, patient 0002.1980 February - 1980 March. HCAC investigator 1, patient 0003.1980 February - 1980 March. HCAC investigator 1, patient 0004.1980 April - 1980 June. HCAC investigator 1, patient 0005.1980 June. HCAC investigator 1, patient 0006.1980 October - 1980 November. HCAC investigator 1, patient 0007.1980 June - 1980 August. HCAC investigator 1, patient 0008.1980 June - 1980 August. HCAC investigator 1, patient 0010.1980 July - 1980 August. HCAC investigator 1, patient 0011.1980 July. HCAC investigator 1, patient 0012.1980 July - 1980 August. HCAC investigator 1, patient 0013.1980 August - 1980 September. HCAC investigator 1, patient 0014.1980 August - 1980 September. HCAC investigator 1, patient 0015.1980 August - 1980 October. HCAC investigator 1, patient 0016.1980 June - 1980 July. HCAC investigator 1, patient 0017.1980 July - 1980 August. HCAC investigator 1, patient 0018.1980 June - 1980 August. HCAC investigator 1, patient 0019.1981 April - 1981 May. HCAC investigator 1, patient 0020.1981 February - 1981 April. HCAC investigator 1, patient 0021.1980 October - 1981 February. HCAC investigator 1, patient 0022.1980 November - 1980 December. HCAC investigator 1, patient 0023.1980 December - 1981 January. HCAC investigator 1, patient 0024.1980 December. HCAC investigator 1, patient 0025.1979 September - 1979 November. HCAC investigator 1, patient 0026.1979 October - 1979 December. HCAC investigator 1, patient 0027.1979 October - 1980 February. HCAC investigator 1, patient 0028.1979 October - 1980 January. HCAC investigator 1, patient 0029.1979 October - 1980 March. HCAC investigator 1, patient 0030.1979 December - 1980 March. HCAC investigator 1, patient 0031.1979 December - 1980 March. HCAC investigator 1, patient 0032.1980 January - 1980 February. HCAC investigator 1, patient 0033.1980 April - 1980 May. HCAC investigator 1, patient 0034.1980 May - 1980 June. HCAC investigator 1, patient 0035.1980 May - 1980 September. HCAC investigator 1, patient 0036.1980 June - 1980 July. HCAC investigator 1, patient 0037.1980 June - 1980 July. HCAC investigator 1, patient 0038.1980 June - 1980 July. HCAC investigator 1, patient 0039.1980 June. HCAC investigator 1, patient 0040.1980 September. HCAC investigator 1, patient 0041.1980 September - 1980 October. HCAC investigator 1, patient 0042.1980 September. HCAC investigator 1, patient 0043.1980 September, 1981 September. HCAC investigator 1, patient 0044.1980 October - 1980 November. HCAC investigator 1, patient 0045.1980 October - 1980 November. HCAC investigator 1, patient 0046.1981 January - 1981 March. HCAC investigator 1, patient 0047.1981 January - 1981 February. HCAC investigator 1, patient 0048.1980 October - 1980 November. HCAC investigator 1, patient 0049.1981 January - 1981 February. HCAC investigator 1, patient 0050.1981 January, 1981 July. HCAC investigator 1, patient 0051.1980 October - 1980 December. HCAD investigator 2, patient 0061.1980 January - 1980 February. HCAD investigator 2, patient 0062.1980 January - 1980 February. HCAD investigator 2, patient 0063.1980 January - 1980 February. HCAD investigator 2, patient 0064.1980 January - 1980 February, 1981 October. HCAD investigator 2, patient 0065.1980 January - 1980 March. HCAD investigator 2, patient 0066.1980 January - 1980 April. David Healy papers (Collection Biomed 433)
Series 1: Fentress et al. v Shea Communications and Eli Lilly and Company. 1970-2001.
Subseries 1.1: Data from Prozac registration files. Bulk, 1978-1985. 1978-2000. HCAD investigator 2, patient 0067.1980 February - 1980 March. HCAD investigator 2, patient 0068.1980 February - 1980 March. HCAD investigator 2, patient 0069.1980 February - 1980 March, 1981 October. HCAD investigator 2, patient 0070.1980 February - 1980 April. HCAD investigator 2, patient 0071.1980 February - 1980 June. HCAD investigator 2, patient 0072.1980 February - 1980 April. HCAD investigator 2, patient 0073.1980 March - 1980 April. HCAD investigator 2, patient 0074.1980 March - 1980 April. HCAD investigator 2, patient 0075.1980 March - 1980 April. HCAD investigator 2, patient 0076.1980 March - 1980 April. HCAD investigator 2, patient 0077.1980 March - 1980 April. HCAD investigator 2, patient 0078.1980 March - 1980 April, 1981 October. HCAD investigator 2, patient 0079.1980 March - 1980 May. HCAD investigator 2, patient 0080.1980 March - 1980 May. HCAD investigator 2, patient 0081.1980 March - 1980 May. HCAD investigator 2, patient 0082.1980 April - 1980 May. HCAD investigator 2, patient 0083.1980 April - 1980 May. HCAD investigator 2, patient 0084.1980 April - 1980 May. HCAD investigator 2, patient 0085.1980 April - 1980 June. HCAD investigator 2, patient 0086.1980 April - 1980 June. HCAD investigator 2, patient 0087.1980 May - 1980 June. HCAD investigator 2, patient 0088.1980 May - 1980 June. HCAD investigator 2, patient 0089.1980 May - 1980 June. HCAD investigator 2, patient 0090.1980 May - 1980 June, 1981 October. HCAD investigator 2, patient 0091.1980 May - 1980 June, 1980 June - 1981 October. HCAD investigator 2, patient 0092.1980 June - 1980 July. HCAD investigator 2, patient 0093.1980 May - 1980 July. HCAD investigator 2, patient 0094.1980 June - 1980 July, 1981 October. HCAD investigator 2, patient 0095.1980 July - 1980 August. HCAD investigator 2, patient 0096.1980 July - 1980 August. HCAD investigator 2, patient 0097.1980 July - 1980 August. HCAD investigator 2, patient 0098.1980 July - 1980 September. HCAD investigator 2, patient 0099.1980 July - 1980 September. HCAD investigator 2, patient 0100.1980 August - 1980 September. HCAF investigator 1, patient 1006.1981 July. HCAF investigator 1, patient 1008.1981 September. HCAF investigator 1, patient 1022.1981 October - 1981 November. HCAF investigator 1, patient 1051.1981 August. HCAF investigator 1, patient 1052.1981 September. HCAF investigator 1, patient 1056.1981 September - 1981 October. HCAF investigator 1, patient 1061.1981 September. HCAF investigator 1, patient 1067.1981 October - 1981 November. HCAF investigator 1, patient 1078.1981 December. HCAF investigator 1, patient 1079.1981 December. HCAF investigator 1, patient 1080.1981 December. HCAF investigator 1, patient 1089.1982 January. HCAF investigator 1, patient 1111.1981 November. HCAF investigator 1, patient 1118.1981 November - 1981 December. HCAF investigator 1, patient 1128.1981 December - 1982 January. HCAF investigator 1, patient 1129.1982 January. HCAF investigator 1, patient 1133.1982 January. HCAF investigator 1, patient 1161.1982 February. HCAF investigator 1, patient 1164.1982 February - 1982 March. HCAF investigator 1, patient 1167.1982 March. HCAF investigator 2, patient 1202.1981 May. HCAF investigator 2, patient 1208.1981 May. HCAF investigator 2, patient 1209.1981 May. David Healy papers (Collection Biomed 433)
Series 1: Fentress et al. v Shea Communications and Eli Lilly and Company. 1970-2001.
Subseries 1.1: Data from Prozac registration files. Bulk, 1978-1985. 1978-2000. HCAF investigator 2, patient 1210.1981 May. HCAF investigator 2, patient 1214.1981 May. HCAF investigator 2, patient 1220.1981 May - 1981 June. HCAF investigator 2, patient 1225.1981 May. HCAF investigator 2, patient 1234.1981 May. HCAF investigator 2, patient 1236.1981 May. HCAF investigator 2, patient 1237.1981 May. HCAF investigator 2, patient 1239.1981 May. HCAF investigator 2, patient 1243.1981 May. HCAF investigator 2, patient 1248.1981 May - 1981 June. HCAF investigator 2, patient 1249.1981 May. HCAF investigator 2, patient 1264.1981 June. HCAF investigator 2, patient 1275.1981 June. HCAF investigator 2, patient 1278.1981 June. HCAF investigator 2, patient 1279.1981 June. HCAF investigator 2, patient 1281.1981 June. HCAF investigator 2, patient 1287.1981 June. HCAF investigator 2, patient 1294.1981 June. HCAF investigator 2, patient 1295.1981 June - 1981 July. HCAF investigator 2, patient 1296.1981 June. HCAF investigator 2, patient 1297.1981 June - 1981 July. HCAF investigator 2, patient 1300.1981 June. HCAF investigator 2, patient 1312.1981 July. HCAF investigator 2, patient 1319.1981 July. HCAF investigator 2, patient 1326.1981 July. HCAF investigator 2, patient 1327.1981 July - 1981 August. HCAF investigator 2, patient 1337.1981 July - 1981 August. HCAF investigator 2, patient 1339.1981 July - 1981 August. HCAF investigator 2, patient 1347.1981 August. HCAF investigator 3, patient 1408.1982 February. HCAF investigator 3, patient 1413.1982 March - 1982 April. HCAF investigator 3, patient 1416.1982 April - 1982 May. HCAF investigator 3, patient 1422.1982 May. HCAF investigator 4, patient 1460.1981 May. HCAF investigator 4, patient 1463.1981 May. HCAF investigator 4, patient 1475.1981 June. HCAF investigator 4, patient 1491.1981 September. HCAF investigator 4, patient 1493.1981 September. HCAF investigator 4, patient 1499.1981 September. HCAF investigator 4, patient 1506.1981 September. HCAF investigator 4, patient 1508.1981 September. HCAF investigator 4, patient 1510.1981 October. HCAF investigator 4, patient 1512.1981 October. HCAF investigator 4, patient 1514.1981 October - 1981 November. HCAF investigator 4, patient 1520.1981 November. HCAF investigator 4, patient 1531.1981 December. HCAF investigator 4, patient 1533.1981 December - 1982 January. HCAF investigator 4, patient 1535.1982 January. HCAF investigator 4, patient 1547.1982 February - 1982 April. HCAF investigator 4, patient 1554.1982 February. HCAF investigator 4, patient 1567.1982 April. HCAF investigator 4, patient 1570.1982 May. HCAF investigator 5, patient 1625.1981 October. HCAF investigator 5, patient 1643.1981 December. HCAF investigator 5, patient 1649.1981 December. HCAF investigator 5, patient 1677.1982 March. HCAF investigator 5, patient 1701.1982 October. HCAF investigator 5, patient 1702.1982 October. David Healy papers (Collection Biomed 433)
Series 1: Fentress et al. v Shea Communications and Eli Lilly and Company. 1970-2001.
Subseries 1.1: Data from Prozac registration files. Bulk, 1978-1985. 1978-2000. HCAF investigator 6, patient 1759.1981 July - 1981 August. HCAF investigator 6, patient 1762.1981 August. HCAF investigator 6, patient 1765.1981 August. HCAF investigator 6, patient 1775.1981 October. HCAF investigator 6, patient 1795.1981 November -1981 December. HCAF investigator 6, patient 1818.1982 February - 1982 March. HCAF investigator 6, patient 1821.1982 March . HCAF investigator 6, patient 1823.1982 May. HCAF investigator 6, patient 1830.1982 June - 1982 July. HCAF investigator 6, patient 1838.1982 August - 1982 September. HCAF investigator 6, patient 1839.1982 September - 1982 October. HCAF investigator 6, patient 1841.1982 September - 1982 October. HCAF investigator 7, patient 1903.1981 July. HCAF investigator 7, patient 1905.1981 July - 1981 August. HCAF investigator 7, patient 1911.1981 September. HCAF investigator 7, patient 1913.1981 October. HCAF investigator 7, patient 1919.1981 October. HCAF investigator 7, patient 1921.1981 November. HCAF investigator 7, patient 1924.1981 December. HCAF investigator 7, patient 1926.1981 December - 1982 January. HCAF investigator 7, patient 2063.1981 August. HCAF investigator 7, patient 2064.1981 August. HCAF investigator 7, patient 2075.1981 August - 1981 September. HCAF investigator 7, patient 2100.1981 October - 1981 November. HCCG investigator 1, patient 5832.1984 December - 1985 January. HCCG investigator 1, patient 5833.1985 January - 1985 February. HCCG investigator 1, patient 5834.1985 January - 1985 March. HCCG investigator 1, patient 5835.1985 January - 1985 March. HCCG investigator 1, patient 5836.1985 January - 1985 March. HCCG investigator 1, patient 5837.1985 January - 1985 March. HCCG investigator 1, patient 5838.1985 January - 1985 March. HCCG investigator 1, patient 5839.1985 February - 1985 April. HCCG investigator 1, patient 5840.1985 March - 1985 June. HCCG investigator 1, patient 5841.1985 March - 1985 April. HCCG investigator 1, patient 5842.1985 March - 1985 April. HCCG investigator 1, patient 5843.1985 March - 1985 April. HCCG investigator 1, patient 5844.1985 March - 1985 April. HCCG investigator 1, patient 5845.1985 March - 1985 April. HCCG investigator 1, patient 5846.1985 April - 1985 June. HCCG investigator 1, patient 5847.1985 April - 1985 May. HCCG investigator 1, patient 5848.1985 April - 1985 June. HCCG investigator 1, patient 5849.1985 May - 1985 June. HCCG investigator 1, patient 5850.1985 May - 1985 June. HCCG investigator 1, patient 5851.1985 May - 1985 July. HCCG investigator 1, patient 5852.1985 May - 1985 July. HCCG investigator 1, patient 5853.1985 May - 1985 July. HCCG investigator 1, patient 5854.1985 June - 1985 July. HCCG investigator 1, patient 5855.1985 June - 1985 July. HCCG investigator 1, patient 5856.1985 June - 1985 July. HCCG investigator 1, patient 5857.1985 June - 1985 August. HCCG investigator 1, patient 5858.1985 June - 1985 July. HCCG investigator 1, patient 5859.1985 June - 1985 July. HCCG investigator 1, patient 5860.1985 June - 1985 July. HCCG investigator 1, patient 9002.1983 December. HCCG investigator 1, patient 9208.1985 March. HCCG investigator 1, patient 9215.1985 March - 1985 May. HCCG investigator 1, patient 9216.1985 May. HCCG investigator 2, patient 5901.1983 November - 1983 December. David Healy papers (Collection Biomed 433)
Series 1: Fentress et al. v Shea Communications and Eli Lilly and Company. 1970-2001.
Subseries 1.1: Data from Prozac registration files. Bulk, 1978-1985. 1978-2000. HCCG investigator 2, patient 5902.1983 November - 1984 January. HCCG investigator 2, patient 5903.1983 November - 1984 January. HCCG investigator 2, patient 5904.1983 December - 1984 January. HCCG investigator 2, patient 5905.1983 December - 1984 February. HCCG investigator 2, patient 5906.1984 January - 1984 February. HCCG investigator 2, patient 5907.1984 January. HCCG investigator 2, patient 5908.1984 January - 1984 February. HCCG investigator 2, patient 5909.1984 January - 1984 February. HCCG investigator 2, patient 5910.1984 January - 1984 March. HCCG investigator 2, patient 5911.1984 January - 1984 March. HCCG investigator 2, patient 5912.1984 February - 1984 March. HCCG investigator 2, patient 5913.1984 January - 1984 March. HCCG investigator 2, patient 5914.1984 February - 1984 March. HCCG investigator 2, patient 5915.1984 March - 1984 July. HCCG investigator 2, patient 5916.1984 March - 1984 November. HCCG investigator 2, patient 5917.1984 April - 1984 November. HCCG investigator 2, patient 5918.1984 April - 1985 May. HCCG investigator 2, patient 5919.1984 April - 1984 November. HCCG investigator 2, patient 5920.1984 April - 1984 December. HCCG investigator 2, patient 5921.1984 May - 1984 August. HCCG investigator 2, patient 5922.1984 May - 1984 August, 1985 July. HCCG investigator 2, patient 5923.1984 May - 1984 July. HCCG investigator 2, patient 5924.1984 May - 1984 September. HCCG investigator 2, patient 5925.1984 May. HCCG investigator 2, patient 5926.1984 May - 1984 June. HCCG investigator 2, patient 5927.1984 May - 1986 October. HCCG investigator 2, patient 5928.1984 May - 1984 June. HCCG investigator 2, patient 5929.1984 May - 1984 June. HCCG investigator 2, patient 5930.1984 May - 1984 June. HCCG investigator 2, patient 5931.1984 May. HCCG investigator 2, patient 5932.1984 May - 1984 July. HCCG investigator 2, patient 5933.1984 May - 1985 January. HCCG investigator 2, patient 5934.1984 June. HCCG investigator 2, patient 5935.1984 June - 1984 August. HCCG investigator 2, patient 5936.1984 June - 1984 July. HCCG investigator 2, patient 5937.1984 June - 1984 July. HCCG investigator 2, patient 5938.1984 June - 1985 February. HCCG investigator 2, patient 5939.1984 June - 1988 January. HCCG investigator 2, patient 5940.1984 July - 1984 August. HCCG investigator 2, patient 5941.1984 July - 1987 December. HCCG investigator 2, patient 5942.1984 July - 1985 December. HCCG investigator 2, patient 5943.1984 July - 1984 August. HCCG investigator 2, patient 5944.1984 July - 1984 August. HCCG investigator 2, patient 5945.1984 July - 1988 March. HCCG investigator 2, patient 5946.1984 August - 1985 January. HCCG investigator 2, patient 5947.1984 August - 1988 March. HCCG investigator 2, patient 5948.1984 September - 1985 November. HCCG investigator 2, patient 5949.1984 September - 1985 May. HCCG investigator 2, patient 5950.1984 September - 1985 December. HCCG investigator 2, patient 5951.1984 September - 1984 December. HCCG investigator 2, patient 5952.1984 September - 1984 November. HCCG investigator 2, patient 5953.1984 October - 1985 May. HCCG investigator 2, patient 5954.1984 October - 1987 September. HCCG investigator 2, patient 5955.1984 October - 1987 December. HCCG investigator 2, patient 5956.1984 October - 1986 August. HCCG investigator 2, patient 5957.1984 November - 1988 February. HCCG investigator 2, patient 5958.1984 November - 1984 December. HCCG investigator 2, patient 5959.1984 November - 1985 January. David Healy papers (Collection Biomed 433)
Series 1: Fentress et al. v Shea Communications and Eli Lilly and Company. 1970-2001.
Subseries 1.1: Data from Prozac registration files. Bulk, 1978-1985. 1978-2000. HCCG investigator 2, patient 5960.1984 December - 1985 February. HCCG investigator 2, patient 9001.1983 November. HCCG investigator 2, patient 9003.1984 January. HCCG investigator 2, patient 9005.1984 February. HCCG investigator 2, patient 9011.1984 March. HCCG investigator 2, patient 9020.1984 July. HCCG investigator 2, patient 9021.1984 July. HCCG investigator 2, patient 9025.1984 July - 1984 August. HCCG investigator 2, patient 9052.1984 August - 1984 September. Subseries 1.2: Fentress court proceedings.1994 October - 1994 December. Scope and Content
Subseries 1.2 contains transcripts and videos of the Fentress court proceedings, which
were held from October 13, 1994 to December 12, 1994. Legal court proceedings.1994 October 13 - 1994 December 12. Videos of Fentress case proceedings (14 tapes).1994 October - 1994 December. Subseries 1.3: Case evidence.1970-1994. Scope and Content
Subseries 1.3 contains evidence submitted in the Fentress case. This largely consists of
depositions and exhibits, including important memos and reports in the history of SSRI
research that were brought to light through litigation. Some items of interest within the
case’s exhibits include Investigational New Drug (IND) submissions, drug experience
reports, data on suicide attempts, and monitor correspondence. This collection does not
include the case docket sheet to indicate when evidentiary items were introduced.
Researchers may request the docket sheet for this case by using the Public Access to
Court Electronic Records service (PACER) (http://www.pacer.gov/). Organization and Arrangement
Whenever possible, court records in subseries 1.3 were organized chronologically with
corresponding exhibits filed directly after their associated deponent. Some deposition
exhibits were already organized by date (1970-1994, undated) when received, with
chronologically organized front matter and file dividers. The original order of those files
was maintained. Other exhibits did not correspond to a deposition within the collection,
and those exhibits were organized alphabetically by last name (Brickler - Wernicke).
There may be some duplicate copies of named exhibits found within the chronologically
Deposition of Max W. Talbott.1992 June 4. Exhibits 1-2 of deposition for Max W. Talbott.1991 October 9-1992 June 4. Deposition of David T. Wong.1994 January 12. Second deposition of Max W. Talbott.1994 January 13. Exhibits 1-2 of second deposition for Max W. Talbott.1989 December 6-1989 December 7. Deposition of David L. Dunner.1994 January 17. Deposition and exhibits 1-12 for Irwin Slater.1970 November 12-1979 November 28, 1994 January 28-1994 January 29. Resumption of deposition of David T. Wong.1994 April 13. [Deposition of John Heiligenstein].1994 April 28-1994 April 29. [Partial exhibit of deposition for Richard Wood].1979 July 23. Deposition of Robert Zerbe.1994 May 13. Deposition of Charles Beasley (1 of 3).1994 May 17-1994 May 18. Deposition of Charles Beasley (2 of 3).1994 May 17-1994 May 18. Deposition of Charles Beasley (3 of 3).1994 May 17-1994 May 18. Exhibits 1-16 of deposition for Charles Beasley (1 of 2).1985 April 3-1991 September 21. David Healy papers (Collection Biomed 433)
Series 1: Fentress et al. v Shea Communications and Eli Lilly and Company. 1970-2001.
Subseries 1.3: Case evidence. 1970-1994. Exhibits 17-27 of deposition for Charles Beasley (2 of 2).1980 February 3-1994 August 30. Deposition of W. Leigh Thompson.1994 July 20-1994 July 22. Deposition of Gary D. Tollefson.1994 July 26. Resumption of deposition of Robert Zerbe.1994 August 9. Deposition of Hans Weber.1994 September 10. Exhibits 1-9 of deposition for Hans Weber.1984 May 25-1997 October 8. Deposition of H.N. Schulze-Solce.1994 September 16. Exhibits 1-13 of deposition for H.N. Schulze-Solce.1986 July 3-1994 January 31. Plaintiff's exhibits 110 and 117 of deposition for H.N. Schulze-Solce.1990 November 13 - 1990 September 14. Exhibit 1 of deposition for Gregory Brickler.circa 1984-1990. Exhibits 1-2, 6-10 of deposition for Gregory Enas.circa 1985-1993. Exhibits 11-21 of deposition for Gregory Enas.circa 1985-1993. Exhibits 1-12 of deposition for Melissa Humbert.1984 September 4-1990 October Exhibits 1-22 of deposition for James Kotsanos.1990-1992. Exhibits 1-14 of deposition for Janet Potvin.1984 April 6-1993 October 27. Exhibits 1-12 of deposition for Mary Sayler.1990-1991. Exhibits 1-13 of deposition for Jamie Street.1989 September 6 - 1991 April 29. Exhibit 16 of deposition for Al Webber.1990 July. Exhibit 14 of deposition for Joe Wernicke.1986 October 3. Undated exhibits of depositions (1 of 2).1970-1994. Scope and Content
Amundson #13; Beasley #20; Brown #1-22; Enas (note and written results); Enas
#21; Fuller #2; Heiligenstein # 1; Heiligenstein #5; Heiligenstein #22; Humbert #2;
Humbert #8; Humbert #9; Kotsanos #22; Mesner #5; Mesner #27
Undated exhibits of depositions (2 of 2).1970-1994. Scope and Content
Russell #20; Russell #21; Sayler #2; Sayler #3; Sayler #8; Sayler #10; Street #5;
Street #6; Leigh Thompson #36; Vicki Thompson #6; Weinstein #10; Weinstein #26;
Wernicke #23; Wheadon #17; Wong #6; Wood #17; Zapapas #12; Zapapas #16;
Zapapas #18; Zapapas #22; Zapapas #25; Zapapas #27
Exhibits of depositions, 1970-1978.1970 November 12-1978 August 2. Scope and Content
1970 November 12: Slater #2; 1974 April 26: Fuller #9; 1974 July 15: Wong #7; 1974
August: Fuller #12; 1977; October 3: Slater #1; 1978 May 18: Fuller #1; 1978 May 18:
Exhibits of depositions, 1979.1979 January - 1979 December. Scope and Content
1979 January 10: Slater #6; 1979 March 9: Lord #9; 1979 June 14: Slater #3; 1979
July 23: Fuller #11; 1979 July 23: Slater #8; 1979 August 3: Slater #12; 1979 August
15: Slater #9; 1979 September 6: Slater #4; 1979 September 19: Slater #5; 1979
November 21: Slater #10; 1979 November 28: Slater #7; 1979 December 24: Slater
Exhibits of depositions, 1980-1981.1980 February-1981 December. Scope and Content
1980 February 3: Beasley #22; 1980 March 11: Beasley #21; 1981 January 9: Beasley
#19; 1981 May 12: Fuller #10; 1981 December 23: Dobbs #6
David Healy papers (Collection Biomed 433)
Series 1: Fentress et al. v Shea Communications and Eli Lilly and Company. 1970-2001.
Subseries 1.3: Case evidence. 1970-1994. Exhibits of depositions, 1982.1982 February - 1982 June. Scope and Content
1982 February 19: Beasley #27; 1982 February 22: Dobbs #1; 1982 April 6: Beasley
#25; 1982 April 9: Stark #7; 1982 May 28: Dobbs #5; 1982 June 16: Dobbs #8
Exhibits of depositions, 1983.1983 January - 1983 December. Scope and Content
1983 January 20: Ashbrook #6; 1983 August 17: Ashbrook #14; 1983 August 24:
Dobbs #2; 1983 October 4: Stark #3; 1983 November 14: Leigh Thompson #26; 1983
December 15: Stark #4; 1983 December 16: Lord #17
Exhibits of depositions, 1984 April - December.1984 April - 1984 December. Scope and Content
1984 April 6: Potvin #1; 1984 April 23: Potvin #2; 1984 May 25: Wernicke #4; 1984
June 8: Wernicke #1; 1984 June 22: Stark #2; 1984 June 26: Wheadon #6; 1984 June
28: Potvin #3; 1984 July 6: Potvin #4; 1984 July 11: Weinstein #3; 1984 July 30: Zerbe
#17; 1984 August 6: Mesner #3; 1984 August 23: Wernicke #2; 1984 October 22:
Weinstein #4; 1984 October 29: Mesner #4; 1984 October 31: Weinstein #5; 1984
November 13: Wood #9; 1984 December 3: Ashbrook #10; 1984 December 6: Potvin
#5; 1984 December 17: Stark #6; 1984 December 19: Potvin #6
Exhibits of depositions, 1985.1985 January - 1985 December. Scope and Content
1985 January 23: Leigh Thompson #28; 1985 January 29: Wernicke #5; 1985 February
12: Wernicke #27; 1985 February 21: Leigh Thompson #37; 1985 February 26:
Wernicke #7; 1985 February 27: Wernicke #6; 1985 March 13: Enas #8; 1985 March
20: Ashbrook #16; 1985 March 22: Zerbe #27; 1985 March 27: Wernicke #9; 1985
March 28: Beasley #7; 1985 April 2: Wheadon #7; 1985 April 4: Zerbe #26; 1985 April
10: Ashbrook #5; 1985 April 19: Wernicke #12; 1985 June 5: Wernicke #25; 1985 June
18: Ashbrook #2; 1985 June 24: Ashbrook #1; 1985 June 26: Enas #9; 1985 June 28:
Wernicke #26; 1985 July 25: Mesner #21; 1985 August 20: Wernicke #11; 1985
August 29: Tauscher #8; 1985 August 29: Wernicke #22; 1985 September 3: Mesner
#11; 1985 September 10: Wood #4; 1985 September 25: Talbott #7; 1985 October 4:
Talbott #5; 1985 October 7: Talbott #6; 1985 October 22: Humbert #1; 1985
November 13: Zerbe #19; 1985 November 13: Wernicke #4; 1985 December 18:
Exhibits of depositions, 1986 (1 of 2).1986 January - 1986 June. Scope and Content
1986 January 23: Weinstein #9; 1986 January 23: Weinstein #9a; 1986 January 30:
Wernicke #16; 1986 February 19: Ashbrook #12; 1986 April 2: Leigh Thompson #39;
1986 June 3: Zerbe #15; 1986 June 16: Russell #16
Exhibits of depositions, 1986 (2 of 2).1986 July - 1986 December. Scope and Content
1986 July 1: Wernicke #17; 1986 July 2: Wernicke #15; 1986 July 3: Solce #7; 1986
July 10: Wernicke #18; 1986 October 3: Wernicke #19; 1986 October 3: Wernicke
#14; 1986 October 8: Wernicke #13; 1986 October 15: Beasley #18; 1986 October
17: Wernicke #14 (duplicate label for unique material?); 1986 October 20: Wheadon
#16; 1986 November 24: Wernicke #16 from D. Gunn case; 1986 December 3:
Wernicke #13 from D. Gunn case; 1986 December 4: Wernicke #17 from D. Gunn
case; 1986 December 8: Wernicke #11; 1986 December 10: Solce #5; 1986
December 12: Solce #6; 1986 December 15: Wernicke #12
David Healy papers (Collection Biomed 433)
Series 1: Fentress et al. v Shea Communications and Eli Lilly and Company. 1970-2001.
Subseries 1.3: Case evidence. 1970-1994. Exhibits of depositions, 1987.1987 January - 1987 December. Scope and Content
1987: Street #13; 1987: Russell #22; 1987 January 27: Wernicke #9; 1987 January
30: Wernicke #3; 1987 February 3: Wernicke #8; 1987 February 10: Dunner #6; 1987
February 13: Dunner #5; 1987 March 11: Ashbrook #11; 1987 June 2: Wernicke #6;
1987 June 23: Wood #18; 1987 June 24: Humbert #6; 1987 July 22: Wheadon #5;
1987 September 9: Leigh Thompson #40; 1987 October 26: Weber #7; 1987
December 3: Wernicke #1; 1987 December 4: Wernicke #30; 1987 December 4:
Wernicke #29; 1987 December 8: Wernicke #31; 1987 December 10: Wernicke #28;
Exhibits of depositions, 1988.1988 January - 1988 December. Scope and Content
1988 January 15: Mesner #7; 1988 January 18: Bryson #3; 1988 January 20: Wernicke
#7; 1988 February 5: Wheadon #15; 1988 February 16: Wernicke #5; 1988 February
17: Wernicke #2; 1988 April 12: Humbert #10; 1988 April 14: Humbert #5; 1988 April
29: Solce # 8; 1988 June 13: Wheadon #12; 1988 July 7: Wheadon #13; 1988 August
18: Lord #18; 1988 September 19: Enas #18; 1988 December 22: Talbott #11
Exhibits of depositions, 1989 January - May.1989 January - 1989 May. Scope and Content
1989 January 13: Tauscher #5; 1989 February 22: Wheadon #29; 1989 May 12: Vicki
Thompson #5; 1989 May 19: Zerbe #18; 1989 May 23: Amundson #16
Exhibits of depositions, 1989 August - December.1989 August - 1989 December. Scope and Content
1989 August 2: Tauscher #3; 1989 August 11: Fuller #5; 1989 August 23: Weber #9;
1989 August 25: Street #8; 1989 August 30: Weinstein #13; 1989 September 6:
Street #9; 1989 September 6: Solce #13; 1989 September 12: Mesner #9; 1989
October 9: Street #12; 1989 October 18: Heiligenstein #20; 1989 October 19: Mesner
#8; 1989 October 23: Wood #25; 1989 October 27: Russell #12; 1989 October 30:
Street #2; 1989 December: Tauscher #6; 1989 December 6: Weinstein #15; 1989
Exhibits of depositions, 1990 January.1990 January 2 - 1990 January 26. Scope and Content
1990: Wheadon #24; 1990 January 2: Heiligenstein #2; 1990 January 5: Street #4;
1990 January 11: Ashbrook #7; 1990 January 24: Beasley #23; 1990 January 26:
Exhibits of depositions, 1990 February - July.1990 February 5 - 1990 July 27. Scope and Content
1990 February 5: Wheadon #27; 1990 February 7: Zerbe #21; 1990 February 7: Zerbe
#20; 1990 February 7: Zerbe #13; 1990 February 8: Street #7; 1990 February 16:
Potvin #11; 1990 February 21: Wheadon #14; 1990 February 23: Heiligenstein #4;
1990 February 27: Tauscher #2; 1990 March 8: Zerbe #6; 1990 March 31: Leigh
Thompson #43; 1990 April 1: Sayler #4; 1990 April 11: Zerbe #5; 1990 April 12:
Amundson #2; 1990 April 13: Street #10; 1990 May 7: Talbott #8; 1990 May 18:
Amundson #6; 1990 May 29: Street #3; 1990 May 30: Potvin #12; 1990 May 30:
Talbott #12; 1990 June 1: Enas #19; 1990 June 14: Lord #16; 1990 July 11: Tauscher
#1; 1990 July 18: Humbert #7; 1990 July 18: Wheadon #3; 1990 July 19: Amundson
#1; 1990 July 25: Webber #18; 1990 July 27: Amundson #5; 1990 July 27: Sayler #1;
1990 July 27: Webber #9; 1990 July 27: Ashbrook #8
David Healy papers (Collection Biomed 433)
Series 1: Fentress et al. v Shea Communications and Eli Lilly and Company. 1970-2001.
Subseries 1.3: Case evidence. 1970-1994. Exhibits of depositions, 1990 August - October.1990 August 3 - 1990 October 24. Scope and Content
1990 August: Wheadon #2; 1990 August 3: Wheadon #25; 1990 August 6: Leigh
Thompson (e-mail); 1990 August 9: Kotsanos #8; 1990 August 16: Kotsanos #6; 1990
August 17: Kotsanos #16; 1990 August 22: Kotsanos #19; 1990 August 27: Russell
#2; 1990 September 12: Zerbe #22; 1990 September 14: Wood #7; 1990 September
14: Zerbe #16; 1990 September 14: Wheadon #1; 1990 September 14: Weinstein
#34; 1990 September 17: Wood #6; 1990 September 18: Amundson #12; 1990
September 19: Street #11; 1990 September 20: Kotsanos #20; 1990 September 21:
Russell #17; 1990 September 24: Amundson #3; 1990 September 25: Mesner #1;1990 September 25: Kotsanos #13; 1990 September 28: Potvin #14; 1990 October 2:
Zerbe #23; 1990 October 3: Leigh Thompson #5; 1990 October 10: Wheadon #26;
1990 October 10: Talbott #2; 1990 October 11: Humbert #3; 1990 October 11: Sayler
#9; 1990 October 11: Webber #4; 1990 October 22: Sayler #9; 1990 October 24:
Exhibits of depositions, 1990 November - December.1990 November 7- 1990 December 21. Scope and Content
1990 November: Wheadon #20; 1990 November 7: Leigh Thompson #11; 1990
November 7: Zerbe #31; 1990 November 13: Wood #24; 1990 November 14:
Kotsanos #3; 1990 November 14: Kotsanos #4; 1990 November 14: Weinstein #20;
1990 November 14: Talbott #7; 1990 November 28: Beasley #13; 1990 November 30:
Wood #15; 1990 November 30: Tollefson #5; 1990 December 3: Leigh Thompson
Exhibits of depositions, 1991 January.1991 January . Scope and Content
1991: Vicki Thompson #4; 1991: Fuller #4; 1991: Beasley #24; 1991 January 14:
Tauscher #9; 1991 January 18: Kotsanos #2
Exhibits of depositions, 1991 February.1991 February 7 - 1991 February 15. Scope and Content
1991 February 7: Amundson #4; 1991 February 10: Fuller #13; 1991 February 13:
Talbott #3; 1991 February 15: Heiligenstein #15; 1991 February 15: Mesner #12
Exhibits of depositions, 1991 March - May.1991 March 6 - 1991 May 30. Scope and Content
1991 March 6: Zapapas #15; 1991 March 15: Zapapas #3; 1991 March 21: Zapapas
#29; 1991 March 27: Webber #13; 1991 March 28: Kotsanos #21; 1991 March 29:
Wheadon #10; 1991 April 2: Zerbe #28; 1991 April 3: Russell #16; 1991 April 4: Fuller
#6; 1991 April 12: Talbott #10; 1991 April 15: Leigh Thompson #3; 1991 April 17:
Wood #20; 1991 April 22: Zapapas #9; 1991 April 22: Enas #16; 1991 April 29: Street
#1; 1991 April 30: Amundson #8; 1991 May: Heiligenstein #21; 1991 May 3: Tollefson
#2; 1991 May 7: Enas #11; 1991 May 8: Ashbrook #15; 1991 May 10: Zapapas #10;
1991 May 15: Wheadon #9; 1991 May 15: Webber #2; 1991 May 24: Russell #3; 1991
David Healy papers (Collection Biomed 433)
Series 1: Fentress et al. v Shea Communications and Eli Lilly and Company. 1970-2001.
Subseries 1.3: Case evidence. 1970-1994. Exhibits of depositions, 1991 June.1991 June 4 - 1991 June 24. Scope and Content
1991 June 3: Kotsanos #9; 1991 June 4: Amundson #7; 1991 June 5: Tollefson #3;
1991 June 6: Webber #15; 1991 June 9: Leigh Thompson #38; 1991 June 11: Wernicke
#24; 1991 June 11: Ashbrook #13; 1991 June 11: Zerbe #24; 1991 June 12: Zerbe
#32; 1991 June 13: Mesner #30; 1991 June 14: Wheadon #18; 1991 June 16:
Kotsanos #15; 1991 June 17: Potvin #13; 1991 June 19: Enas #6; 1991 June 20:
Talbott #13; 1991 June 19: Mesner #19; 1991 June 20: Kotsanos #12; 1991 June 20:
Mesner #20; 1991 June 20: Zapapas #17; 1991 June 21: Sayler #7; 1991 June 24:
Exhibits of depositions, 1991 July - August.1991 July 2 - 1991 August 28. Scope and Content
1991 July 2: Tollefson #10; 1991 July 10: Mesner #26; 1991 July 16: Zerbe #25; 1991
July 22: Enas #3; 1991 July 23: Russell #13; 1991 July 23: Mesner #17; 1991 July 23:
Mesner #25; 1991 July 29: Mesner #28; 1991 July 29: Wood #22; 1991 July 31:
Mesner #23; 1991 July 31: Mesner #18; 1991 August 1: Enas #4; 1991 August 6:
Mesner #24; 1991 August 7: Zapapas #7; 1991 August 9: Webber #8; 1991 August
12: Sayler #6; 1991 August 15: Zapapas #5; 1991 August 15: Mesner #29; 1991
August 19: Heiligenstein #3; 1991 August 20: Wheadon #28; 1991 August 23: Sayler
#12; 1991 August 26: Zapapas #26; 1991 August 28: Amundson #10
Exhibits of depositions, 1991 September - December.1991 September 5 - 1991 December 17. Scope and Content
1991 September 5: Zerbe #7; 1991 September 13: Talbott #17; 1991 September 14:
Enas #5; 1991 September 16: Dunner #7; 1991 September 17: Sayler #5; 1991
September 20: Enas #22; 1991 September 20: Leigh Thompson #2; 1991 September
21: Wheadon #23; 1991 October 15: Zapapas #21; 1991 October 21: Mesner #16;
1991 October 21: Tauscher #4; 1991 November 22: Webber #11; 1991 December 10:
Zapapas #24; 1991 December 17: Zapapas #30
Exhibits of depositions, 1992 January.1992 January 3 - 1992 January 31. Scope and Content
1992: Wood #13; 1992: Wood #14; 1992 January 3: Webber #12; 1992 January 15:
Webber #1; 1992 January 23: Wong #2; 1992 January 28: Zapapas #11; 1992 January
29: Wong #3; 1992 January 31: Weinstein #25
Exhibits of depositions, 1992 February - December.1992 February 4 - 1992 December 31. Scope and Content
1992 February 4: Wong #5; 1992 February 12: Wheadon #21; 1992 February 28:
Wong #1; 1992 February 28: Mesner #13; 1992 March 13: Webber #14; 1992 March
17: Weinstein #30; 1992 March 20: Fuller #7; 1992 April: Webber #5; 1992 April 8:
Wong #4; 1992 April 13: Weinstein #33; 1992 April 30: Weinstein #29; 1992 May 7:
Wood #12; 1992 June 3: Potvin #8; 1992 June 4: Zapapas #20; 1992 July 17: Potvin
#7; 1992 August 6: Weinstein #31; 1992 October 5: Tollefson #7; 1992 October 12:
Enas #17; 1992 November: Kotsanos #10; 1992 November 2: Vicki Thompson #3;
1992 December 8: Fuller #8; 1992 December 24: Leigh Thompson #21; 1992
December 30: Wood #11; 1992 December 31: Tollefson #6
Exhibits of depositions, 1993 January - March.1993 January 4 - 1993 March 17. Scope and Content
1993 January 4: Enas #20; 1993 January 20: Leigh Thompson #4; 1993 January 29:
Heiligenstein #18; 1993 February 3: Zapapas #23; 1993 March 25: Heiligenstein #6;
David Healy papers (Collection Biomed 433)
Series 1: Fentress et al. v Shea Communications and Eli Lilly and Company. 1970-2001.
Subseries 1.3: Case evidence. 1970-1994. Exhibits of depositions, 1993 April - December.1993 April 19 - 1993 December. Scope and Content
1993 April 19: Lord #19; 1993 August 17: Wheadon #19; 1993 August 27: Zapapas
#14; 1993 September 22: Zapapas #28; 1993 December: Dunner #2
Exhibits of depositions, 1994 January - August.1994 January 14 - 1994 August 24. Scope and Content
1994 January 14: Dunner #1a, b, c; 1994 January 15: Fuller #1; 1994 January 17:
Zerbe #4; 1994 January 17: Dunner #8 a, b, c; 1994 January 31: Wheadon #8; 1994
August 12: Lord #1; 1994 August 24: Brown #8
Other information on fluoxetine safety.1985 September 9 - 1992 July. Oswald Judgment (exhibit).1998. Videos of Fentress depositions (25 tapes).1994 May 12 - 1994 September 16. Subseries 1.4: Correspondence.1997-2001. Scope and Content
Subseries 1.4 consists of Healy’s personal and legal correspondence regarding fluoxetine
and the Fentress case between 1997 and 2001. Legal correspondence with Healy.1997 November 12 - 2000 November 1. Healy's personal correspondence regarding fluoxetine.1998 March - 2001 December. Series 2: Other legal cases.1972-2001. Processing/Project Information
Videos in Series 2 were minimally processed at the box level. Scope and Content
Series 2 contains textual and video material related to other legal cases, including Forsyth v.
Eli Lilly and Company (1999 verdict), Motus v. Pfizer (2001 verdict), Tobin v. SmithKline
Beecham Pharmaceuticals (2001 verdict), and Greer v. Eli Lilly and Company (2006 verdict).
Many of these cases were outlined as important case histories in David Healy’s book, LetThem Eat Prozac. Most materials relate to the Forsyth case, so subseries were not created.
Contents include court proceedings, Eli Lilly documents, depositions and exhibits from the
Forsyth case; a memorandum from the Tobin case to limit testimony of Dr. Healy and Dr.
Maltsberger; and video depositions of David Healy and Jan Fawcett from the Miller et al. v.
Pfizer Inc. and Motus v. Pfizer Inc. cases, respectively. Forsyth case's legal court proceedings.1999 March 19. Eli Lilly documents from Forsyth case, vol. 1 (1 of 2).1972-1995 June 15. Eli Lilly documents from Forsyth case, vol. 1 (2 of 2).1972-1986. Eli Lilly documents from Forsyth case, vol. 2 (1 of 2).1986-1993. Eli Lilly documents from Forsyth case, vol. 2 (2 of 2).1986-1993. Miscellaneous plaintiff's exhibits from Forsyth case.1978 May 18 - 1991 April 15. Plaintiff's response for admissions in Forsyth case.circa 1999. Deposition of Randolph D. Neal from Forsyth case.1996 March 8. Deposition of Martin H. Teicher from Greer case.1996 October 29 - 1996 October 30. Tobin case memorandum to limit testimony of Dr. Healy and Dr. Maltsberger.2001 PAL format videos of deposition of David Healy (Miller et al. v Pfizer Inc.) (7) and videos of deposition of Jan Fawcett (Motus v Pfizer Inc.) (2).2000 March 27-28, 2001 October 11. David Healy papers (Collection Biomed 433)
Series 3: The Psychopharmacologists. Bulk, 1992-2000. 1950-2001. Series 3: The Psychopharmacologists.Bulk, 1992-2000.1950-2001. Processing/Project Information
Videos in Series 3 were minimally processed at the box level. Scope and Content
Series 3 holds interviews that were conducted with seventy-eight prominent researchers in
the field and which cover significant topics in the history of psychopharmacology. Together,
these interviews comprise David Healy’s three-volume oral history of psychopharmacology
entitled The Psychopharmacologists. Some interviewees include Robert Spitzer (an American
researcher and a major architect of the DSM-III and DSM-III R versions of the Diagnostic and
Statistical Manual of Mental Disorders), Leslie Iversen (a British researcher of
catecholamines and, in particular, dopamine), Arvid Carlsson (a Swedish scientist who
researched dopamine’s effects on Parkinson’s disease), Judith Rapoport (an American
researcher of adolescent psychotic disorders and Chief of the Child Psychiatry Branch within
the NIMH since 1984), Myra Weissman (an American researcher who helped develop
interpersonal psychotherapy with Gerald Klerman), Frank Ayd (an American psychiatrist who
was granted the first FDA permit to use Thorazine to treat schizophrenia), Louis Lasagna (An
American physician who was one of the first people to conduct Randomized Controlled Trials
and who was known for his revision of the Hippocratic Oath), and Mogens Schou (a Danish
physician whose research on Lithium led to its use as a treatment for bipolar disorder).
Topics covered in the transcripts include but are not limited to the discovery of
chlorpromazine (the first drug developed with specific antipsychotic action), antidepressants,
and opioid peptides; the catecholamine hypothesis; receptors in psychiatry; the founding of
institutions such as the Collegium Internationale Neuro-Psychopharmacologicum (CINP) and
the British Association of Psychopharmacology (BAP); psychopharmacology in children; and
discussions of drug development and clinical trials. This series also contains professional
correspondence with publishing companies and pharmaceutical corporations related to the
publication of The Psychopharmacologists, letters between interviewees and David Healy,
scientific articles produced by other researchers, photographs of various interviewees,
interviewees’ reflections on the interview process, and handwritten, collaborative edits on
drafts of the associated interview transcripts. Finally, box 33 of the collection offers a partial
interview schedule that will interest researchers as it may be used to construct the
interviews chronologically. In sum, these materials are a rich source of research on the
history and practice of neuropsychopharmacology. Organization and Arrangement
Original order was maintained for Series 3, as it corresponded to the chapter placement of
interviews within the three volumes of The Psychopharmacologists. The series starts with
Vol. 1: Pierre Pichot: Discovery of chlorpromazine.1994 August - 1995 May. Vol. 1: Julius Axelrod: The discovery of amine reuptake.1994 June - 1994 November. Vol. 1: Arvid Carlsson: The rise of neuropsychopharmacology.1994 December 11 - 1998 May. Vol. 1: Frank Ayd: The discovery of antidepressants.1994 May - 1995 June. Vol. 1: Alan Broadhurst: Before and after imipramine.1993 February - 1998 May. Vol. 1: Silvio Garattini: The role of independent science in psychopharmacology. 1993 August - 1995 October. Vol. 1: Heinz Lehmann: Psychopharmacotherapy.1994 March - 1998 April. Vol. 1: Hanns Hippius: The founding of the CINP and discovery of clozapine.1994 June - 1996 March. Vol. 1: Hannah Steinberg: Bridging the gap: psychology, pharmacology and after. 1993 July - 1996 July. Vol. 1: Jonathan Cole: The evaluation of psychotropic drugs.1994 March - 1995 May. Vol. 1: Alec Coppen: Biological psychiatry in the United Kingdom.1994 January 9 - 1994 October. Vol. 1: Jules Angst: The myths of psychopharmacology.1994 May - 1996 June. Vol. 1: George Beaumont: The place of clomipramine in psychopharmacology.1992 October - 1993 April. David Healy papers (Collection Biomed 433)
Series 3: The Psychopharmacologists. Bulk, 1992-2000. 1950-2001. Vol. 1: Donald Klein: Reaction patterns to psychotropic drugs.1994 May - 1996 January. Vol. 1: Herman van Praag: Psychiatry and the march of folly.1993 December - 1998 Vol. 1: Merton Sandler: The place of chemical pathology in psychopharmacology. 1990 November - 1998 September. Vol. 1: Floyd Bloom: Neurophysiology and psychopharmacology of addiction.1994 April - 1998 April. Vol. 1: Alexandra Delini-Stula: The changing face of psychotropic drug development. 1994 September - 1994 November. Vol. 1: Gordon Claridge: The role of individual differences in psychopharmacology. 1993 December - 1998 May. Vol. 1: Malcolm Lader: Psychopharmacology: clinical and social.1993 November - 1995 January. Vol. 1: Herbert Meltzer: A career in biological psychiatry.1994 March - 1995 October. Vol. 1: Brian Leonard: The role of behavioural pharmacology in drug development. 1994 January - 1995 August. Vol. 1: John Hughes: The discovery of the opioid peptides.1994 January - 1994 September. Vol. 1: Peter Waldmeier: From mental illness to neurodegeneration.1993 February - 1995 April. Vol. 1: Tom Ban: They used to call it psychiatry.1994 June - 1999 April. Vol. 2: Therese Lemperiere: In the beginning in Paris.1997 March - 1997 July. Vol. 2: Len Cook: Behaviour, pharmacology, and chloropromazine.1997 March. Vol. 2: Paul Janssen: From haloperidol to risperidone.1996 February - 1996 October. Vol. 2: Joseph Brady: The origins of behavioural pharmacology.1996 April - 1997 January. Vol. 2: Roland Kuhn: From imipramine to levoprotiline: the discovery of antidepressants.1996 July - 1998 July. Vol. 2: Max Lurie: The enigma of isoniazid.1997 May - 1998 May. Vol. 2: Louis Lasagna: Back to the future: evaluation and drug development 1948-1998.1995 January - 1998 April. Vol. 2: Linford Rees: The place of clinical trials in the development of psychopharmacology.1993 March - 1998 May. Vol. 2: Joel Elkes: Towards footings in a new science: psychopharmacology, receptors, and the pharmacy within (1 of 2).1997 March - 1997 June. Vol. 2: Joel Elkes: Towards footings in a new science: psychopharmacology, receptors, and the pharmacy within (2 of 2).1997 March - 1997 June. Vol. 2: Leo Hollister: From hypertension to psychopharmacology: a serendipitous career.1997 January - 1998 April. Vol. 2: Michael Shepherd: Psychopharmacology: specific and non-specific.1995 June - 1995 August. Vol. 2: Mogens Schou: Lithium.1997 January - 1997 February. Vol. 2: George Simpson: Clinical psychopharmacology.1996 November - 1998 April. Vol. 2: Gerald Curzon: From neurochemistry to neuroscience.1996 October - 1998 Vol. 2: Leslie Iversen: Neuroscience and drug development.circa 1993-1998. Vol. 2: Jeff Watkins: Excitatory amino acids: From basic science to therapeutic applications.1988 - 1998 May. Vol. 2: Irving Gottesman: Predisposed towards predispositions.circa 1993-1998. Vol. 2: Juan Lopez-Ibor: Personality, disease, and psychopharmacology.1996-1998. Vol. 2: Oakley Ray: A psychologist in American neuropsychopharmacology.1995 March - 1998 April. Vol. 2: David Wheatley: The foundation of the British Association of Psychopharmacology.1962 April - 1998 April. Vol. 2: Ian Stolerman: Behavioural pharmacology.1997 April - 1998 July. Vol. 2: Per Bech: Measurement and organization in psychopharmacology.1984 - 1996 April. David Healy papers (Collection Biomed 433)
Series 3: The Psychopharmacologists. Bulk, 1992-2000. 1950-2001. Vol. 2: Myrna Weissman: Gerald Klerman and psychopharmacology.1996 June - 1997 Vol. 2: Isaac Marks: Marketing the evidence.1996 March - 1996 April. Vol. 2: Vagn Pedersen and Klaus Bogoeso: Drug hunting.1996 November - 1998 April. Vol. 2: Roger Pinder: Approaching rationality?.circa 1996-1998. Vol. 2: Paul Leber: Managing uncertainty.1994 June - 1998 June. Vol. 3: Pierre Lambert, Jean Guyotat, Paul Broussolle, Paul Brouillot, Patrick Lemoine, and Jacques Greffe: Exploring a New World: The birth of psychopharmacotherapy (1 of 4).1998 October - 1999 January. Vol. 3: Pierre Lambert, Jean Guyotat, Paul Broussolle, Paul Brouillot, Patrick Lemoine, and Jacques Greffe: Exploring a New World: The birth of psychopharmacotherapy (2 of 4).1998 October 29. Vol. 3: Pierre Lambert, Jean Guyotat, Paul Broussolle, Paul Brouillot, Patrick Lemoine, and Jacques Greffe: Exploring a New World: The birth of psychopharmacotherapy (3 of 4).circa 1998-2000. Vol. 3: Pierre Lambert, Jean Guyotat, Paul Broussolle, Paul Brouillot, Patrick Lemoine, and Jacques Greffe: Exploring a New World: The birth of psychopharmacotherapy (4 of 4).1972 January - 2000 February. Vol. 3: Oldrich Vinar: A psychopharmacology that nearly was.1998 November 1 - 1999 February 2. Vol. 3: Joseph Knoll: The psychopharmacology of life and death (1 of 2).1998 October 22 - circa 2000. Vol. 3: Joseph Knoll: The psychopharmacology of life and death (2 of 2).1952-2000 February. Vol. 3: Joseph Schildkraut: The catecholamine hypothesis.1998 December 16 - 2000 February 10. Vol. 3: Alec Jenner: Catatonia, pink spots, and antipsychiatry.1961-2000 January. Vol. 3: Dick Barlow: Receptors and chemists.1953 August/ September - 2000 January. Vol. 3: Robert Stephenson: Receptors and classical pharmacology.1998 April - 2000 January. Vol. 3: George Ashcroft: The receptor enters psychiatry (1).1960 June - 2000 January. Vol. 3: Donald Eccleston: The receptor enters psychiatry (2).1997 October - circa Vol. 3: Solomon Snyder: Visualizing receptors and beyond.1994 March - 1999 April. Vol. 3: Fridolin Sulser: From the presynaptic neurone to the receptor to the nucleus. 1994 May - 1999 April. Vol. 3: Teruo Okuma: The discovery of the psychotropic effects of carbamazepine. 1983 December - circa 2000. Vol. 3: Toshi-Hiro Kobayakawa: Psychopharmaceuticals in Japan.1997 November 21 - circa 2000. Vol. 3: Michio Toru: Neurotransmitter research in Japan.1998 July 12 - 2000 February. Vol. 3: Rachel Gittelman Klein: Children and psychopharmacology.1998 December 15 - circa 2000. Vol. 3: Judith Rapoport: Phenomenology, psychopharmacotherapy, and child psychiatry.1998 December 15 - 2000 February. Vol. 3: Robert Domenjoz: From DDT to imipramine.1951 September - 1998 March. Vol. 3: Raymond Battegay: Forty-four years of psychiatry and psychopharmacology. 1997 April 23 - 2000 February. Vol. 3: Samuel Guze: The neo-Kraepelinian revolution.1998 June 1 - 1998 October 28. Vol. 3: Robert Spitzer: A manual for diagnosis and statistics.1999 March - 1999 Vol. 3: Max Fink: Neglected disciplines in psychopharmacology: pharmaco-EEG and electroshock.1998 May - 2000 February. Vol. 3: Ian Oswald: The hypnotic business.1998 January - 2000 February. David Healy papers (Collection Biomed 433)
Series 3: The Psychopharmacologists. Bulk, 1992-2000. 1950-2001. Vol. 3: David Sheehan: Angles on panic.1994 November - 1998 November. Vol. 3: Edward Warawa: From neuroleptics to antipsychotics.1999 May - 2000. Vol. 3: Pierre Simon: Twenty-first century drug development.1998 February - 1998 September. Vol. 3: Jean Thuillier: Ten years that changed psychiatry (1 of 2).1998 September - 1999 February. Vol. 3: Jean Thuillier: Ten years that changed psychiatry (2 of 2).1956 October - 1998 December. Correspondence with publishers for The Psychopharmacologists.1952-2000 January. Partial interview schedule for The Psychopharmacologists and other works.circa 1994-2000. 1 video on Mogens Schou, 1 video on Jean Thuillier, 3 Betacam digital tapes on Jean Thuillier.1985 - 1999 August. David Healy papers (Collection Biomed 433)
GENDER MEDICINE/VOL. 7, NO. 4, 2010 Commentary Sex, Gender, and Pharmaceutical Politics: From Drug Development to Marketing Jill A. Fisher, PhD1; and Lorna M. Ronald, PhD2 1Center for Biomedical Ethics & Society, Vanderbilt University, Nashville, Tennessee; and 2Interdisciplinary Studies Program, John Jay College (City University of New York), New York, New York Background
Myotonia Congenita Introduction This paper is to provide information for school staff regarding a condition known as myotonia congenita which has been diagnosed in your student, _______________________________________________________ (student name). The following is for informational purposes only and is not to be used for diagnosis or treatment of myotonia congenita. Myotonia Co
David Healy papers (Collection Biomed 433)